{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Incidence rate of acute and late toxicities of grade 3 or higher was measured after each treatment cycle was over. The most common late toxicities defined as toxicity occurring more than 90 days after treatment included laryngeal edema and xerostomia.","groups":[{"description":"Nab-Paclitaxel, Cetuximab, Cisplatin, and Intensity-modulated radiation therapy (IMRT)","id":"OG000","title":"Single Arm: Chemotherapy With Concurrent Radiation Therapy"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"6 months within the end of treatment","title":"Number of Participants With Acute and Late Toxicities","type":"SECONDARY","unitOfMeasure":"Participants"}